Management of bevacizumab toxicity for cancer therapy
10.3760/cma.j.issn.1673-422X.2011.09.021
- VernacularTitle:贝伐单抗治疗恶性肿瘤不良反应的策略
- Author:
Xiajun LIU
;
Yongning ZHOU
;
Da ZHAO
- Publication Type:Journal Article
- Keywords:
Bevacizumab;
Drug toxicity;
Safety management
- From:
Journal of International Oncology
2011;38(9):711-714
- CountryChina
- Language:Chinese
-
Abstract:
Bevacizumab is an efficient and low-toxicity monoclonal antibody towards serum ventricular endothelial growth factor.At present,bevacizumab has been approved by FDA to use clinically for kinds of cancer,such as colorectal cancer,lung cancer,kidney cancer and breast cancer.As more and more patients received bevacizumab cliniclly,it's toxicities are also focused on increasingly.
